Zimbabwe has rejected a substantial American healthcare agreement worth $367m (272 million pounds) over five years over Washington's demand for sensitive biological samples.
This rejection came to light after a internal memorandum from December was disclosed, revealing that President Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesman later stated that the US was demanding access to genetic material for research and commercial purposes but refused to share the benefits from any future treatments.
"We must now begin the difficult and regrettable process of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had furnished more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for more talks to find a deal agreeable to all parties so the nation's critical HIV programme can be sustained.
Broader Implications
This rejection follows a similar case in neighbouring Kenya, where a court halted a related deal with the US after concerns were filed about the safety of Kenyans' health data.
Since returning to the presidency last year, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
USAID had overseen aid for the US government, but Trump argued its expenditure was "wasteful" and his government was seeking direct bilateral deals to boost openness and accountability.
Based on reports, 16 African countries have so far agreed to these new agreements, representing more than $18.3bn of fresh investment.
Details of the Declined Deal
The funds for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration would have delivered extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy through US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to share its genetic material and health information over an extended period, with no equivalent promise of benefiting from any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," Mangwana explained.
"Effectively, our nation would supply the raw materials for medical research with no certainty that the resulting innovations would be available to our people should a new pandemic arise."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the global health body and its pursuit of bilateral deals were upending frameworks previously set up through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing system created to deal with future global health emergencies.
"This framework is designed to guarantee that when a country provides its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We welcome further dialogue with our American counterparts on how subsequent collaboration could be designed in a manner that respects the sovereignty and dignity of both nations."
Medical Community Reaction
A leading public health body expressed it understood the official position, but urged that negotiations should continue given that a large portion of the nation's Aids initiatives relied on external financing.
"If technical issues arise, such as those involving data governance or implementation frameworks, these can frequently be resolved via technical clarification and negotiated safeguards," the group added.
The situation emphasises the complex challenges between receiving much-needed foreign assistance and protecting a country's data in an increasingly interconnected world.